Anticoagulation monitoring

Journal of Pharmacy Practice

Volumn 17, Issue 5, 2004, Pages 317-326

  Smythe, Maureen A ^a,b   Caffee, Anne ^c,d  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c SHENANDOAH UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

ACT; Anticoagulation; aPTT; Heparin; INR; Warfarin

Indexed keywords

ARGATROBAN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; COUMARIN; ECARIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PROTAMINE; THROMBIN INHIBITOR; THROMBOPLASTIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; INTERNATIONAL STANDARD UNIT; LABORATORY TEST; META ANALYSIS; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; SURGICAL TECHNIQUE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

EID: 10644258010     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/0897190004271775     Document Type: Review

References (82)

1. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy, laboratory monitoring of unfractionated heparin therapy. Arch Path Lab Med. 1998;122:782-798.
2. National Committee for Clinical Laboratory Standards. Collection, Transport and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays: Approved Guideline. 3rd ed. H21-A3. Wayne, Penn: National Committee for Clinical Laboratory Standards; 1998.
3. Granger CB, Hirsh J, Califf RM, et al. Activated thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation. 1996;93:870-878.
4. Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin. Ann Intern Med. 1993;119:104-109.
5. Reed SV, Haddon ME, Denson KWE. An attempt to standardize the aPTT for heparin monitoring using the P.T. ISI/INR system of calibration: results of a 13 centre study. Thromb Res. 1994;74:515-522.
6. Patel VB, Moliterno DJ. Bedside activated partial thromboplastin time monitoring: just a matter of time? Am Heart J. 1999;137:8-11.
7. Reiner JS, Coyne KS, Lundergan CF, et al. Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn. 1994;32:49-52.
8. Taylor CT, Petros WP, Ortel TL. Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring. Pharmacotherapy. 1999;19:383-387.
9. Despotis GJ, Hogue CW, Santoro SA, et al. Effect of heparin on whole blood activated partial thromboplastin time using a portable, whole blood coagulation monitor. Crit Care Med. 1995;23:1674-1679.
10. Smythe MA, Koerber JM, Westley SJ, et al. Use of the activated partial thromboplastin time for heparin monitoring. Am J Clin Pathol. 2001;115:148-155.
11. Reich DL, Yanakakis MJ, Vela-Cantos FP, et al. Comparison of bedside coagulation monitoring tests with standard laboratory tests in patients after cardiac surgery. Anesth Analg. 1993;77:673-679.
12. Werner M, Gallagher JV, Ballo MS, et al. Effect of analytic uncertainty of conventional and point-of-care assays of activated partial thromboplastin time on clinical decisions in heparin therapy. Am J Clin Pathol. 1994;102:237-241.
13. Basu D, Gallus A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;287:324-327.
14. Chiu HM, Hirsh J, Yung WL, et al. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood. 1977;49:171-184.
15. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med. 1986;315:1109-1114.
16. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154:49-56.
17. Turpie AGG, Robinson JG, Doyle DJ, et al. Comparison of high dose with low dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989;320:352-357.
18. Kitchen S, Preston FE. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost. 1996;75:734-739.
19. Manzato F, Mengoni A, Grilenzoni G. Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring. Clin Chem Lab Med. 1998;36:975-980.
20. Hirsch J, Raschke R. Heparin and low molecular weight heparin. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:188s-203s.
21. Koerber JM, Smythe MA, Begle RL, et al. Correlation of activated clotting time and activated partial thromboplastin time to plasma heparin concentration. Pharmacotherapy. 1999;19:922-931.
22. Baker BA, Adelman MD, Smith PA, et al. Inability of the activated partial thromboplastin time to predict heparin levels: time to reassess guidelines for heparin assays. Arch Intern Med. 1997;157:2475-2479.
23. Fenyvesi T, Jorg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost. 2002;28:361-367.
24. Pötzsch B, Madlener K, Seelig C, et al. The whole blood ecarin clotting time assay allows rapid and accurate monitoring of the anticoagulant response of r-hirudin during cardiopulmonary bypass. Thromb Hemost. 1997;77:920-925.
25. Hafner G, Roser M, Nauck M. Methods for the monitoring of direct thrombin inhibitors. Semin Thromb Hemost. 2002;28:425-430.
26. Lidon RM, Theroux P, Juneau M, et al. Initial experience with a direct antithrombin, Hirulog, in unstable angina: anticoagulant, antithrombotic and clinical effects. Circulation. 1993;88:1495-1501.
27. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20:318-329.
28. Pötzsch B, Hund S, Madlener K, et al. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time. Thromb Res. 1997;86:373-383.
29. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with heparin induced thrombocytopenia: a prospective study. Circulation. 1999;99:73-80.
30. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation. 1999;100:587-593.
31. Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96:846-851.
32. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838-1843.
33. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849-1856.
34. Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res. 2003;110:73-82.
35. Hattersley PG. Activated coagulation time of whole blood. JAMA. 1980;140:1173-1175.
36. Smythe MA, Koerber JM, Nowak SN, et al. Correlation between activated clotting time and activated partial thromboplastin time. Ann Pharmacother. 2002;36:7-11.
37. Nath FC, Muller DVM, Rosenschein U. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time. Can J Cardiol. 1993;9:797-801.
38. Melandri G, Branzi A, Traini AM, et al. On the value of the activated clotting time for heparin monitoring in acute coronary syndromes. Am J Cardiol. 1993;71:469-471.
39. Cipolle RJ, Uden DL, Gruber SA. Evaluation of a rapid monitoring system to study heparin pharmacokinetics and pharmacodynamics. Pharmacotherapy. 1990;10:367-372.
40. Popma JJ, Berger B, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:576s-599s.
41. Chang RJ, Doherty TM, Goldberg SL. How does warfarin affect the activated clotting time? Am Heart J. 1998;136:477-479.
42. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation. 1997;95:614-617.
43. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of glycoprotein IIb/IIIa integrin on blockade of activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC Trial). Am J Cardiol. 1995;75:559-562.
44. Wang JS, Lin CY, Hung WT, et al. In vitro effects of aprotinin on activated clotting time measured with different activators. J Thorac Cardiovasc Surg. 1992;104:1135-1140.
45. Henry TS, Satran D, Knox LL. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular weight heparin? Am Heart J. 2001;142:590-593.
46. Lawrence M, Mixon TA, Cross D, et al. Assessment of anticoagulation using activated clotting times in patients receiving intravenous enoxaparin during percutaneous coronary intervention. Catheter Cardiovasc Interv. 2004;61:52-55.
47. Murray DJ, Brosnahan J, Pennell B, et al. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Surg. 1997;11:24-28.
48. Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg. 1994;108:1076-1082.
49. Despotis GJ, Joist JG, Hogue CW, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation: a prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1995;110:46-54.
50. Gibbs NM, Weightman WM, Thackray M. Evaluation of the TAS coagulation analyzer for monitoring heparin effect in cardiac surgical patients. J Cardiothorac Vasc Anesth. 1998;12:536-541.
51. Wallock M, Jeske WP, Bakhos M, et al. Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test. Perfusion. 2001;16:147-153.
52. Fitch JCK, Geary KLB, Mirto GP, et al. Heparin management test versus activated coagulation time during cardiovascular surgery: correlation with anti-Xa activity. J Cardiothorac Vasc Anesth. 1999;13:53-57.
53. Leyvi G, Shore-Lesserson L, Harrington D, et al. An investigation of a new activated clotting time "MAX-ACT" in patients undergoing extracorporeal circulation. Anesth Analg. 2001;92:578-583.
54. Toffaletti JG, McDonnell EH, Welsby I, et al. Implementing a new method for activated clotting time: comparisons between the Hemochron and the Actalyke-MaxACT Systems. Point Care. 2003;2:125-128.
55. American Heart Association. Heart Disease and Stroke Statistics: 2004 Update. Dallas, Tex: American Heart Association; 2003.
56. Ogilby JD, Kopelman HA, Klein LW, Agarwal JB. Adequate heparinization during PTCA: assessment using activated clotting times. Catheter Cardiovasc Diagn. 1989;18:206-209.
57. Chew DP, Bhatt DL, Lincoff M, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001;103:961-966.
58. Cho L, Kottke-Marchant KK, Lincoff AM, et al. Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations. Am J Cardiol. 2003;19:1110-1113.
59. Lewis BE, Matthai WH, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2002;57:177-184.
60. Swan AK, St. Peter JV, Lambrecht LJ, et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy. 2000;20:756-770.
61. Hursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small molecule, direct thrombin inhibitor. Semin Thromb Hemost. 1997;23:503-516.
62. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention, REPLACE-2 randomized trial. JAMA. 2003;289:853-863.
63. Smythe MA, Mattson JC, Koerber KM. The heparin anti-Xa therapeutic range: are we there yet? Chest. 2002;121:303-304.
64. Kovacs MJ, Kenney M, MacKinnon KM, et al. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (daltaparin) or unfractionated heparin. Clin Lab Haematol. 1999;21:55-60.
65. Kitchen S, Preston FE. The therapeutic range of heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost. 1996;75:734-739.
66. Koerber JM, Mattson JC, Smythe MA. Variability in antifactor Xa assay procedures [abstract P2051]. J Thromb Hemostas. 1(suppl 1).
67. Laposata, M, Green, K, Elizabeth MVC, et al. The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban: College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy. Arch Pathol Lab Med. 1998;122:799-807.
68. Brophy DF, Wazny LD, Gehr TW, et al. The pharmacokinetics of subcutaneous enoxaparin in end stage renal disease. Pharmacotherapy. 2001;21:169-174.
69. Sanderink GJ, Guimart CG, Ozoux ML, et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin over 4 days in patients with renal impairment. Thromb Res. 2002;105:225-231.
70. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular weight heparins in special populations. Pharmacotherapy. 2001;21:218-234.
71. Schulman S. Unresolved issues in anticoagulant therapy. J Thromb Haemost. 2003;1:1464-1470.
72. Ng VL, Levin J, Corash L, Gottfried EL. Failure of the international normalized ratio to generate consistent results within a local medical community. Am J Clin Pathol. 1993;99:689-694.
73. Pollar L, Keown M, Shepherd SA, et al. The effect of freeze drying and freeze drying additives on the prothrombin time and the international sensitivity index. J Clin Pathol. 1999;52:744-748.
74. Van den Besselaar AMHP, Chantarangkul V, Tripodo A. A comparison of two sodium citrate concentrations in two evacuated blood collection systems for prothrombin time and ISI determination. Thromb Haemost. 2000;84:664-667.
75. Adcock DM, Kressin DC, Marlar RA. The effect of time and temperature variables on routine coagulation tests. Blood Coag Fibrinolysis. 1998;9:463-470.
76. Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. Ann Intern Med. 2003;138:714-719.
77. Tripodi A, Chantarangkul V, Mannucci PM. Near-patient testing devices to monitor oral anticoagulant therapy. Br J Haematol. 2001;113:847-852.
78. Cromheecke ME, Levi M, Cooly LP, et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomized cross-over comparison. Lancet. 2000;356:97-102.
79. Warkentin TE. Platelet count monitoring and laboratory testing for heparin induced thrombocytopenia: recommendations of the College of American Pathologists. Arch Pathol Lab Med. 2002;126:1415-1423.
80. Bates SM, Grand'Maison A, Johnston M, et al. A latex D-dimer reliably excludes venous thromboembolism. Arch Intern Med. 2001;161:447-453.
81. Kruip MJ, Slob MJ, Schijen JH, et al. Use of a clinical decision rule in combination with D-dimer concentration in diagnostic workup of patients with suspected pulmonary embolism: a prospective management study. Arch Intern Med. 2002;162:1631-1635.
82. Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA. 2003;290:1071-1074.